EGFR and cancer: Moreover, the nanoparticle based on co-delivery of EGFR drugs and integrin αvβ3 inhibitors also reveals great potential for use in the other chemotherapeutic agents, which provide a favorable platform for combined drugs delivery in cancer therapy.